获得性免疫耐受2.0。

IF 8.9 2区医学 Q1 SURGERY

American Journal of Transplantation Pub Date : 2025-03-07 DOI:10.1016/j.ajt.2025.02.020

Qizhi Tang

引用次数: 0

摘要

肝移植后，一些患者自发地对移植物产生耐受，可以在保持功能、生化和组织学完整性的同时停止免疫抑制。自发肝移植耐受率从13%到80%不等，取决于移植后的时间和免疫抑制停药的资格标准(1)。最近结束的两项肝移植免疫抑制停药试验LIFT和OPTIMAL发现，在经过广泛筛选和选择的接受医学监督的免疫抑制停药的患者中，自发肝移植耐受率几乎相同，为16%(1)。2).确定耐受性的前瞻性生物标志物将有助于选择免疫抑制停药的耐受性患者，并可能为指导新耐受性方案的设计提供潜在的免疫学机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Acquired immune tolerance 2.0

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of Transplantation 医学-外科

CiteScore

18.70

自引率

4.50%

发文量

346

审稿时长

26 days

期刊介绍： The American Journal of Transplantation is a leading journal in the field of transplantation. It serves as a forum for debate and reassessment, an agent of change, and a major platform for promoting understanding, improving results, and advancing science. Published monthly, it provides an essential resource for researchers and clinicians worldwide. The journal publishes original articles, case reports, invited reviews, letters to the editor, critical reviews, news features, consensus documents, and guidelines over 12 issues a year. It covers all major subject areas in transplantation, including thoracic (heart, lung), abdominal (kidney, liver, pancreas, islets), tissue and stem cell transplantation, organ and tissue donation and preservation, tissue injury, repair, inflammation, and aging, histocompatibility, drugs and pharmacology, graft survival, and prevention of graft dysfunction and failure. It also explores ethical and social issues in the field.